Restoration of latent inhibition by olanzapine but not haloperidol in entorhinal cortex-lesioned rats

Psychopharmacology

Volumn 150, Issue 2, 2000, Pages 226-232

  Coutureau, E ^a   Gosselin, O ^a   Di Scala, G ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

D3 receptor; Entorhinal cortex; Haloperidol; Latent inhibition; Olanzapine; Schizophrenia

Indexed keywords

HALOPERIDOL; OLANZAPINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; ENTORHINAL CORTEX; HISTOPATHOLOGY; LATENT INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; ENTORHINAL CORTEX; HALOPERIDOL; INHIBITION (PSYCHOLOGY); MALE; PIRENZEPINE; RATS; RATS, LONG-EVANS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 0033919768     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130000434     Document Type: Article

References (52)

1. Amaral DG, Witter MP (1995) Hippocampal formation. In: Paxinos G (ed) The rat nervous system. Academic Press, San Diego, pp 443-493
2. Arnold SE (1999) Cognition and neuropathology in schizophrenia. Acta Psychiatr Scand Suppl 395:41-50
3. Arnold SE, Ruscheinsky DD, Han LY (1997) Further evidence of abnormal cyotarchitecture of the entorhinal cortex in schizophrenia using spatial point pattern analyses. Biol Psychiatry 42:639-647
4. Arnt J, Skarfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101
5. Bardgett ME, Csernansky JG (1996) Antipsychotic drug action after lesions to the hippocampus or frontal cortex. In: Csernansky JG (ed) Handbook of experimental pharmacology: antipsychotics (vol 102). Springer, Berlin Heidelberg New York, pp 267-288
6. Baruch I, Hemsley DR, Gray JA (1988) Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Mental Dis 176:598-606
7. Bouthenet M-L, Souil E, Martres M-P, Sokoloff P, Giros B, Schwartz J-C (1991) Localisation of dopamine D3 receptor mRNA in the rat using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 564:203-219
8. Brog JS, Salyapongse A, Deutch AY, Zahm DS (1993) The patterns of afferent innervation of the core and shell in the 'accumbens' part of the rat ventral striatum: immunohistochemical detection of retrogradely transported fluoro-gold. J Comp Neurol 338:255-278
9. Bymaster FP, Calligaro MO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsycho-pharmacology 14:87-96
10. Clark AJM, Feldon J, Rawlins JNP (1992) Aspiration lesions of rat ventral hippocampus disinhibit responding in conditioned suppression or extinction, but spare latent inhibition and the partial reinforcement extinction effect. Neuroscience 48:821-829
11. Coutureau E, Galani R, Majchrzak M, Gosselin O, Di Scala G (1999) Entorhinal but not hippocampal or subicular lesions disrupt Latent Inhibition. Neurobiol Learning Memory 72:143-157
12. Deutch AY, Lewis DA, Whitehead RE, Elsworth JD, Iadarola MJ, Redmond DE, Roth RH (1996) Effects of D2 dopamine receptor antagonists on Fos protein expression in the striatal complex and entorhinal cortex of the non-human primate. Synapse 23:182-191
13. Dunn LA, Awater GE, Kilts CD (1993) Effects of antipsychotics drugs on latent inhibition: sensitivity and specificity of animal behavioural model of clinical drug action. Psychopharmacology 112:315-323
14. Ellenbroek BA, Cools AR (1990) Animal models with construct validity for schizophrenia. Behav Pharmacol 1:469-490
15. Fink-Jensen A, Kristensen P (1994) Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain. Neurosci Lett 182:115-118
16. Goldsmith SK, Joyce JN (1994) Dopamine D2 receptor expression in hippocampus and parahippocampal cortex of rat, cat, and human in relation to tyrosine hydroxylase-immunoreactive fibers. Hippocampus 4:354-373
17. Gosselin O, Oberling P, Di Scala G (1996) Antagonism of amphetamine-induced disruption of latent inhibition by the atypical antipsychotic olanzapine in rats. Behav Pharmacol 7:820-826
18. Gray JA, Feldon J, Rawlins JNP, Hemsley DR, Smith AD (1991) The neuropsychology of schizophrenia. Behav Brain Sci 14:1-84
19. Guo N, Klitenick MA, Tham CS, Fibiger HC (1995) Receptor mechanisms mediating clozapine-induced c-Fos expression in the forebrain. Neuroscience 65:747-756
20. Han J-G, Gallagher M, Holland P (1995) Hippocampal lesions disrupt decrements but not increments in conditioned stimulus processing. J Neurosci 15:7323-7329
21. Honey RC, Good M (1993) Selective hippocampal lesions abolish the contextual specificity of latent inhibition and conditioning. Behav Neurosci 107:23-33
22. Hurley MJ, Subbs CM, Jenner P, Marsden CD (1996) Dopamine D3 receptors are not involved in the induction of c-Fos m-RNA by neuroleptics drugs: comparison of the dopamine D3 receptor antagonist GR103691 with typical and atypical neuroleptics. Eur J Pharmacol 318:283-293
23. Jarrard LE (1993) On the role of the hippocampus in learning and memory in the rat. Behav Neural Biol 60:9-26
24. Kaye H, Pearce JM (1987) Hippocampal lesions attenuate latent inhibition of a CS and of a neutral stimulus. Psychobiology 15:293-299
25. Killcross AS, Robbins TW (1993) Differential effects of intraaccumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm. Psychopharmacology 110:479-489
26. Larson ER, Ariano MA (1995) D3 and D2 dopamine receptors: visualization of cellular expression patterns in motor and limbic structures. Synapse 20:325-337
27. Louillot A, Choulli MK (1998) Asymmetrical increases in dopamine turnover in the nucleus accumbens and lack of changes in locomotor responses following unilateral dopaminergic depletions in the entorhinal cortex. Brain Res 778:150-157
28. Lubow RE (1989) Latent inhibition and conditioned attention theory. In: Lubow RE (ed) Cambridge University Press, Cambridge, UK
29. Lubow RE, Moore AU (1959) Latent inhibition: the effect of non-reinforced preexposure to the conditioned stimulus. J Comp Physiol Psychol 52:415-419
30. McFarland DJ, Kostas J, Drew WM (1978) Dorsal hippocampal lesions: effects of preconditioning CS exposure on flavor aversion. Behav Biol 22:398-404
31. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262:545-551
32. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC (1993) The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 2:281-293
33. Moran PM, Fischer TR, Hitchcock JM, Moser PC (1996) Effects of clozapine on latent inhibition in the rat. Behav Pharmacol 7:42-48
34. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic Press, New York
35. Reilly S, Harley C, Revusky S (1993) Ibotenate lesions of the hippocampus enhance latent inhibition in conditioned taste aversion and increase resistance to extinction in conditioned taste preference. Behav Neurosci 107:996-1004
36. Robertson GS, Fibiger HC (1992) Neuroleptics increase c-Fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46:315-328
37. Robertson GS, Fibiger HC (1996) Effects of olanzapine on regional c-Fos expression in rat forebrain. Neuropsychopharmacology 14:105-110
38. Schmajuk NA, Lam YW, Christiansen BA (1994) Hippocampectomy disrupts latent inhibition of the rat eyeblink conditioning. Physiol Behav 55:597-601
39. Sun YS, Susuki M, Kurashi T, Murata M, Kurashi M (1998) Expression of Fos protein in the limbic regions of the rat following haloperidol decanoate. Brain Res 791:125-136
40. Swanson LW (1982) The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study. Brain Res Bull 9:321-353
41. Tai C-T, Cassaday HJ, Feldon J, Rawlins JNP (1995) Both electrolytic and excitotoxic lesions of nucleus accumbens disrupt latent inhibition of learning in rats. Neurobiol Learning Memory 64:36-48
42. Tarrasch R, Weiner I, Rawlins JNP, Feldon J (1992) Disruption of latent inhibition by interrupting the subicular input to nucleus accumbens and its antagonism by haloperidol. J Psychopharmacol 6:111
43. Totterdel S, Meredith GE (1997) Topographical organization of projections from the entorhinal cortex to the striatum of the rat. Neuroscience 78:715-729
44. Vahid-Ansari F, Robertson GS (1996) 7-OH-DPAT differentially reverses clozapine- and haloperidol-induced increases in Fos-like immunoreactivity in the rodent forebrain. Eur J Neurosci 8:2605-2611
45. Warburton EC, Joseph MH, Feldon J, Weiner I, Gray JA (1994) Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron. Psychopharmacology 114:657-664
46. Weiner I, Feldon J (1987) Facilitation of latent inhibition by haloperidol. Psychopharmacology 91:248-253
47. Weiner I, Feldon J (1997) The switching model of latent inhibition: an update of neural substrate. Behav Brain Res 88:11-25
48. Weiner I, Lubow RE, Feldon J (1984) Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology 83:194-199
49. Weiner I, Lubow RE, Feldon J (1988) Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol Biochem Behav 30:871-878
50. Yee BK, Feldon J, Rawlins JNP (1995) Latent inhibition in rats is abolished by NMDA-induced loss in the retrohippocampal region, but this lesion effect can be prevented by systemic haloperidol treatment. Behav Neurosci 109:227-240
51. Yee BK, Feldon J, Rawlins JNP (1997) Cytotoxic lesions of the retrohippocampal region attenuate latent inhibition but spare the partial reinforcement extinction effect. Exp Brain Res 115:247-256
52. Zhang W, Bymaster FP (1999) The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5-HT2A and muscarinic receptors. Psychopharmacology 141:267-278